Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Director Sells 124,690 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Peter Neupert sold 124,690 shares of Adaptive Biotechnologies stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.15, for a total value of $3,135,953.50. Following the completion of the transaction, the director owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. This trade represents a 48.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Adaptive Biotechnologies Price Performance

ADPT traded up $0.93 during trading on Wednesday, reaching $25.49. 2,145,752 shares of the company were exchanged, compared to its average volume of 2,579,911. The company’s 50-day moving average is $21.75 and its two-hundred day moving average is $17.24. The company has a market cap of $4.07 billion, a price-to-earnings ratio of -62.17 and a beta of 2.08. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $26.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. During the same period in the previous year, the firm earned ($0.17) EPS. The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies in the 4th quarter worth $28,000. EverSource Wealth Advisors LLC lifted its stake in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its stake in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Adaptive Biotechnologies during the fourth quarter valued at about $51,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Piper Sandler increased their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen increased their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.